Comparison of genomic alterations in Epstein–Barr virus‐positive and Epstein–Barr virus‐negative diffuse large B‐cell lymphoma
Cancer Medicine · 2024-02 · 13 (4)
DOI: 10.1002/cam4.6995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 08.03.2024. Verfasst von Fang Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First People's Hospital of Foshan, Foshan, Guangdong, China. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foshan Science Technology and Medical Foundation under grant, 14th Five-year high level specialty construction project in Foshan, Special fund of Foshan Summit plan under grant.
Abstract (Originalsprache)
Background
Epstein–Barr virus (EBV)‐positive diffuse large B‐cell lymphoma (EBV‐posDLBCL) is an aggressive B‐cell lymphoma that often presents similar morphological and immune phenotype features to that of EBV‐negative DLBCL (EBV‐negDLBCL). Aims and Methods To better understand their difference in genomic landscape, we performed whole‐exome sequencing (WES) of EBV‐posDLBCL and EBV‐negDLBCL.
Results
This analysis revealed a new mutational signature 17 (unknown) and signature 29 (smoking) in EBV‐posDLBCL as well as a specific mutational signature 24 (associated with aflatoxin) in EBV‐negDLBCL. Compared with EBV‐negDLBCL, more somatic copy number alterations (CNAs) and deletions were detected in EBV‐posDLBCL ( p = 0.01). The most frequent CNAs specifically detected in EBV‐posDLBCL were gains at 9p24.1 (PDL1 and JAK2), 8q22.2‐q24.23 (DEPTOR and MYC), and 7q31.31‐q32.2 (MET), which were validated in additional EBV‐posDLBCL cases. Overall, 53.7% (22/41) and 62.9% (22/35) of the cases expressed PD‐L1 and c‐MET, respectively, in neoplastic cells, whereas only 15.4% (4/26) expressed c‐MYC. Neoplastic c‐MET expression was positively correlated with PD‐L1 ( p < 0.001) and MYC expression ( p = 0.016). However, EBV‐posDLBCL cases did not show any differences in overall survival between PD‐L1‐, c‐MET‐, or c‐MYC‐positive and ‐negative cases or between age‐related groups. Analysis of the association between somatic mutation load and EBV status showed no difference in the distribution of tumor mutant burden between the two lymphomas ( p = 0.41). Recurrent mutations in EBV‐posDLBCL implicated several genes, including DCAF8L1, KLF2, and NOL9, while in EBV‐negDLBCL, ANK2, BPTF, and CNIH3 were more frequently mutated. Additionally, PIM1 is the most altered gene in all the WES‐detected cases.
Conclusions
Our results confirm that genomic alteration differs significantly between EBV‐posDLBCL and EBV‐negDLBCL, and reveal new genetic alterations in EBV‐posDLBCL. The positive correlation of c‐MET and PD‐L1/c‐Myc expression may be involved in the pathogenesis of EBV‐posDLBCL, which is should be explored prospectively in trials involving MET‐directed therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First People's Hospital of Foshan, Foshan, Guangdong, China.
- Department of Pathology and Molecular Diagnostics, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China.
- Department of Pathology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
- Department of Pathology, Fujian Province Cancer Center, Fuzhou, Fujian, China.
- State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi, China.
- Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan.
ORCID-Profile: Fang Liu
Förderung
- Foshan Science Technology and Medical Foundation under grant
- 14th Five-year high level specialty construction project in Foshan
- Special fund of Foshan Summit plan under grant
Zitieren
APA
Liu, F., Tian, S., Liu, Q., Deng, Y., He, Q., Shi, Q., Chen, G., Xu, X., Yuan, J., Nakamura, S., Karube, K., & Wang, Z. (2024). Comparison of genomic alterations in Epstein–Barr virus‐positive and Epstein–Barr virus‐negative diffuse large B‐cell lymphoma. Cancer Medicine, 13(4). https://doi.org/10.1002/cam4.6995
Vancouver
Liu F, Tian S, Liu Q, Deng Y, He Q, Shi Q, et al. Comparison of genomic alterations in Epstein–Barr virus‐positive and Epstein–Barr virus‐negative diffuse large B‐cell lymphoma. Cancer Medicine. 2024;13(4). doi:10.1002/cam4.6995
BibTeX
@article{Liu2024,
author = {Liu, Fang and Tian, Sufang and Liu, Qing and Deng, Yuanfei and He, Qingyan and Shi, Qianyun and Chen, Gang and Xu, Xiuli and Yuan, Jiayin and Nakamura, Shigeo and Karube, Kennosuke and Wang, Zhe},
title = {Comparison of genomic alterations in Epstein–Barr virus‐positive and Epstein–Barr virus‐negative diffuse large B‐cell lymphoma},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {4},
doi = {10.1002/cam4.6995}
}
EUVIMED